Journal of Oral and Maxillofacial Surgery
Volume 67, Issue 5, Supplement , Pages 19-26 , May 2009

Bisphosphonates—Role in Cancer Therapies

  • Bhoomi Mehrotra, MD

      Affiliations

    • Section Head, Division of Medical Oncology, Long Island Jewish Medical Center, and Associate Professor of Clinical Medicine, Albert Einstein College of Medicine, New Hyde Park, NY
    • Corresponding Author InformationAddress correspondence and reprint requests to Dr Mehrotra: Department of Medicine, Division of Hematology/Oncology, Long Island Jewish Medical Center, 270-05 76th Avenue, New Hyde Park, NY

References 

  1. Gucalp R, Ritch P, Wiernik P, et al. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol. 1992;10:134
  2. Thiebaud D, Jaeger PH, Jacquet AF, et al. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonates AHPrBP. J Clin Oncol. 1988;6:762
  3. Major P, Lartholory A, Joh J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001;19:558
  4. Tian E, Ahan F, Walker R, et al. The role of the Wnt/β-catenin signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349:2483
  5. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med. 1996;334:488
  6. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol. 1998;16:593
  7. Rosen LS, Gordon D, Kaminski M, et al. Long term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Am Cancer Soc. 2003;98:1735
  8. Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002;20:3719
  9. Kyle RA, Yee GC, Sommerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007;25:2464
  10. Lacy MQ, Dispenzeri A, Giertz MA, et al. Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 2006;81:1047
  11. Roodman GD. Biology of osteoclast activation in cancer. J Clin Oncol. 2008;19:3562
  12. Paterson AHG, Powles TJ, Kanis JA, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 1993;11:59
  13. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med. 2005;24:1785
  14. Conte PF, Latreille L, Mauriac F, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multinational randomized controlled trial. J Clin Oncol. 2008;14:2552
  15. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. J Clin Oncol. 1999;17:846
  16. Hillner BE, Ingle JN, Berenson JR, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol. 2000;18:1378
  17. Hillner BE, Ingle JN, Chelbowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21:4042
  18. Lipton A, Steger GTG, Figueroa J, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol. 2007;28:4431
  19. Saad F, Adachi JD, Brown JP, et al. Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol. 2008;33:5465
  20. Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. 2008;26:1051
  21. Coombes RC, Kilbuirn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomized controlled trial. Lancet. 2007;570:559
  22. Gross PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA 17. J Natl Cancer Inst. 2006;97:1262
  23. Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update study BIG 1-98. J Clin Oncol. 2007;25:486
  24. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol. 2001;19:3306
  25. Delmas PD, Balena R, Confravreux E, et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebo-controlled study. J Clin Oncol. 1997;15:955
  26. Hershman DL, McMahon DJ, Crew KD, et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2008;26:4739
  27. Gnant MFX, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2008;25:820
  28. Saarto T, Vehmanen L, Blonqvist C, et al. Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early stage breast cancer. J Clin Oncol. 2008;26:4289
  29. Lester JE, Dodwell D, Omprakash P, et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res. 2008;14:6336
  30. Greenspan SL, Brofsky A, Lembersky BC, et al. Risedronate prevents bone loss in breast cancer survivors: A 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol. 2008;26:2644
  31. Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007;25:829
  32. Bundred NJ, Campbell ID, Davidson N, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole ZO-FAST study results. Cancer. 2008;112:1001
  33. Brufsky A, Bundred N, Coleman R, et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist. 2008;13:503
  34. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008;26:4875
  35. Diel J, Jaschke A, Solomayer EF, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow—A long-term follow-up. Ann Oncol. 2008;19:2007
  36. Powles T, Paterson S, Kanis JA, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol. 2002;20:3219
  37. Saarto T, Blomqvist C, Virkkunen P, et al. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5 year results of a randomized controlled trial. J Clin Oncol. 2001;19:10
  38. Gnant M, Mlineritsch B, Schippinger W. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. New Eng J Med. 2009;360:679
  39. Rosen LS, Gordon D, Tchekmedyian , et al. Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial. J Clin Oncol. 2008;21:3150
  40. Small EJ, Smith MR, Seaman JJ, et al. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium of the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol. 2003;21:4277
  41. Saad F, Gleson DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458
  42. Shahinian RB, Yong-Fang K, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;64:154
  43. Smith MR, McGovern FJ, Zeitman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345:948
  44. Smith MR, McGovern FJ, Zeitman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345:948

 Dr Mehrotra served as a consultant and on the Advisory Board and Speaker's Bureau for Novartis Pharmaceuticals.

PII: S0278-2391(09)00119-0

doi: 10.1016/j.joms.2009.01.012

Journal of Oral and Maxillofacial Surgery
Volume 67, Issue 5, Supplement , Pages 19-26 , May 2009

Article Tools